Protein / RNAi / Genes / RNA / Gene / Drugs / Medicine / Drug / Europe / Boston / Boston blog main / Boston top stories / National blog main / National top stories / New York blog main / New York top stories / San Diego blog main / San Diego top stories / Akcea Therapeutics / Alnylam Pharmaceuticals / European Medicines Agency / FDA / Harvard Pilgrim Health Care / hereditary transthyretin amyloidosis / inotersen / institute for clinical and economic review / Life Sciences / Onpattro / patisiran / Pfizer / tafamidis

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

Posted on: Aug 30, 2018   |   Posted by: Biotech Mag Top

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

The first medicine that uses RNA interference, a method cells employ to mute a gene before it can make a harmful protein, has made its way to Europe. Three weeks after the FDA...

Continue reading ...



Other Posts from Biotech Mag Top